Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, Johnson & Johnson Innovative Medicines, offers insight into the promising evidence of cell therapies and biologic-based treatments for patients with multiple myeloma.
In recent years, several key treatments for multiple myeloma have shown potential to address challenges in the field, such as improving key endpoints like patient survival and response rates and enhancing manufacturing. Speaking to EPR,Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Johnson & Johnson Innovative Medicines, highlights recent developments for the CAR-T cell therapy CARVYKTI (ciltacabtagene-autoleucel-cilta-cel), as well the biologics DARZALEX® (daratumumab), TECVAYLI®▼ (teclistamab) and talquetamab and their overall promise as combination therapies.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Additionally, he shares his predictions for the therapy landscape in five years and why applying a targeted treatment approach is important for the field to progress.
Potential of cell therapies and biologics for multiple myeloma
Clinical data1 has shown that the targeted therapy cilta-cel is “highly effective”, according to Chan. For example, the response rate and overall survival trend seen in CARTITUDE-4 study were “unmatched”.
He explained that patients who received the one-off therapy “survived a lot longer compared to those who received the control therapy, pomalidomide, bortezomib and dexamethasone (PVd)”.
Chan stated that data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting for the biologic TECVAYLI®▼ (teclistamab)2 provide the latest long term follow up for the pivotal Phase I/II MajesTEC-1 study.
For example, in a recent press release,2 Dr Niels van de Donk, Professor of Hematology at Amsterdam University Medical Centers, and principal study investigator, commented that “with the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple myeloma who have limited treatment options”.
On the other hand, another biologic, TALVEY (talquetamab), targets the G protein-coupled receptor 5D (GPRC5D) receptor and “works quite differently to the BCMA target like teclistamab or CAR T; it also binds to the cancer cells and bring it to the cell and destroys it”, Chan added.
For transplant-ineligible patients, the Phase III MAIA study4 demonstrated that daratumumab added to lenalidomide and dexamethasone (D-Rd) provided “a median overall survival of about seven years in first line.” This contrasts with 20 years ago where patients were expected to have survival, according to Chan, of “about a year”.
He emphasised that having the first non-transplant study offering a combination therapy that is not as burdensome as a stem cell transplant, “is really exciting”.
Some cell therapies, Chan explained, can be put into storage “and then when a patient needs it, we take it out and give it to the patient”.
However, in the case of CARVYKTI (ciltacabtagene-autoleucel-cilta-cel), the patient is part of the process: a patient’s T cells are modified to recognise the cancer and then infused back into the patient. As this can take time, one key challenge is how to “scale this out… increase our capacity so we can actually provide patient wherever patients need it”.
He highlighted that J&J has a new manufacturing site opening in Ghent, Belgium, which is intended to increase the company’s cilta-cel capacity. It is the first European production facility for CAR-T therapy.5 The second challenge is that supply is “very limited”. It can be “very difficult” to prioritise patients who will be most benefited from this therapy, he noted.
The treatment landscape in five years
Chan went on to discuss regulatory developments within this indication. He stated that in April, the US FDA’s Oncologic Drugs Advisory Committee (ODAC) approved MRD as a surrogate of disease control to aid accelerated approvals of multiple myeloma treatments.
Based on evidence provided in the briefing document for ODAC’s April meeting on this topic, the International Independent Team for Endpoint Approval of Myeloma MRD (I2TEAMM) concluded that “there is sufficient evidence to support use of MRD as an endpoint for accelerated approval, with progression-free survival (PFS) maintained as a long-term endpoint for confirmation of clinical benefit.”
He envisioned that when put into practise, “in five years we will start to see MRD [being used] as a stopping rule” in patients who are MRD negative.
Positively, Chan remarked that this protocol is being applied in the ongoing Phase III PERSEUS study investigating daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (D-VRd) compared to Velcade, lenalidomide, and dexamethasone (VRd). In patients who become MRD negative after two years of daratumumab and lenalidomide maintenance therapy, the daratumumab treatment is stopped.
Treatment modalities for multiple myeloma
“We will be seeing a lot of biologic combinations” he continued and predicts there will be “more personalised durational therapy”.
Currently, J&J are investigating a “combination of daratumumab and teclistamab in earlier lines. In theory, these two are actually a very good combination,” Chan explained.
He also shared that the ongoing Phase Ib REDIRECTT-1 study is looking at a combination of the two bispecifics teclistamab and talquetamab. “Two different targets: BCMA [and] GPRC5D, join hands to attack cancer”.
Initial results, presented at the 2023 ASCO Annual Meeting, demonstrated “a very high [overall] response rate [of] about 70 percent”, Chan stated. These are patients with extramedullary disease (EMD), who “not only have the blood disease multiple myeloma but also bone manifestations or deposit elsewhere”.
To compare, he highlighted that traditionally in these patients, “the overall response rate would be around the mid 20s, early 30 percent”.
When considering cell therapy, what is “really, really exciting” in the outlook of targeted therapy.
Currently, in some patients the disease can be put under control, he elucidated. “It’s a lot better than 10 years ago, but we’re still not quite there yet… We are bringing cilta-cel in much earlier line in the frontline therapy. In the future, we hope to see multiple myeloma becoming a curable disease”.
In terms of development in the CAR T space, J&J are “looking into shortening the manufacturing time… and also exploring whether we can produce CAR T that is off the shelf. The space in five years will be very, very different but exciting”.
About the interviewee
Edmond Chan is Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, Johnson & Johnson Innovative Medicines. He joined Janssen in 2012 and has led multiple different functions in the organisation, including R&D, local, regional and global Medical Affairs. As part of his role, he focuses on haematological cancers such as multiple myeloma and chronic lymphocytic leukaemia. He is an experienced, UK-trained pharmaceutical physician, specialising in renal medicine, and holds a doctorate in clinical research in solid organ transplantation.
References
CARVYKTI ciltacabtagene autoleucel cilta cel significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma. [Internet] Globe Newswire. 2024. [cited 2024June]. Available from:
https://www.globenewswire.com/news-release/2024/06/03/2892566/0/en/CARVYKTI-ciltacabtagene-autoleucel-cilta-cel-significantly-improved-progression-free-survival-and-deepened-responses-versus-two-standard-therapies-for-patients-with-functional-high.html
TECVAYLI®▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma. [Internet] Globe Newswire. 2024. [cited 2024June]. Available from:
https://www.globenewswire.com/news-release/2024/06/03/2892235/0/en/TECVAYLI-teclistamab-shows-sustained-deep-and-durable-responses-in-patients-with-relapsed-or-refractory-multiple-myeloma.html
DARZALEX® (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma. [Internet] Globe Newswire. 2024. [cited 2024June]. Available from:
https://www.globenewswire.com/news-release/2024/06/03/2892594/0/en/DARZALEX-daratumumab-based-regimens-significantly-improved-clinical-outcomes-in-both-transplant-eligible-and-ineligible-patients-who-are-newly-diagnosed-with-multiple-myeloma.html
Overall Survival Results With Daratumumab, Lenalidomide, And Dexamethasone Versus Lenalidomide And Dexamethasone In Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Phase 3 Maia Study. [Internet] Globe Newswire. 2021. [cited 2024June]. Available from:
https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/330171/thierry.facon.overall.survival.results.with.daratumumab.lenalidomide.and.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2035%2Amarker%3D1284%2Afeatured%3D17286
Janssen to produce innovative cell therapies in Belgium. [Internet] Globe Newswire. 2024. [cited 2024June]. Available from:
https://www.janssen.com/belgium/janssen-invests-european-production-site-cell-therapy-belgium
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.